undamentalytics Newsletter
Sign in

Biodesix Inc (BDSX) stock

Add to watchlist

Add holding +

NASDAQ: BDSX Nasdaq Life Sciences Tools & Services Next results ~November 5, 2026

C+ Fundamentals grade

Biodesix Inc is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Model estimate per share

~$16

Valuation models combined (3)

Base case. Range ~$7.3–$39. Weighted average of 3 models (growth cash-flow model, forward price-to-sales vs peers, revenue-to-maturity model), the growth cash-flow model counting double.

Price vs value

No Buy/Hold/Sell rating is issued: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Biodesix Inc valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders1 buying, 5 selling6 purchases and 20 sales by directors and officers, last 12 monthsInsider trades
  • Funds24 adding, 18 cuttingOf 12 active managers that changed their stake, 9 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Biodesix files

Where Biodesix stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $103m, up 34.5% on a year earlier, faster than the 29.1% growth a quarter earlier. That growth ranks 4 of 46 among the life sciences tools & services companies we cover. Free-cash-flow margin rose to -19.7% from -40.7% a year earlier. Operating margin widened to -20.0% from -44.5%. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 1 of our 7 financial-health checks. Our revenue-to-maturity cash-flow model value is $21.51 a share, against a share price of $24.56.

Source: 10-Q filed August 5, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Biodesix Inc's trailing-twelve-month revenue grew 34.5% year on year, with a free-cash-flow margin of -19.7%. Where it stands out: revenue growth of 34.5% ranks 4 of 54 life sciences tools & services companies we cover. Where it lags: long-term debt as % of assets of 52.5% ranks 32 of 35 life sciences tools & services companies we cover.

Current signal Net margin expanding: TTM net margin reached -27.0%, up 26.7pp year over year.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Fast growth. Revenue grew 34.5% over the last 12 months, against a median of 6.9% for life sciences tools & services companies we cover.
  • Growth speeding up. The growth rate is 5.4 points higher than a quarter earlier.
  • Margins widening. Operating margin is up 24.5 points on a year ago.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Loss-making. Operating margin is -20.0%: costs exceed revenue.
  • Burning cash. Free cash flow was -19.7% of revenue over the last 12 months.
  • Volatile shares. Over the past year the shares showed annualised volatility of 108% and a beta of 1.0 against the S&P 500.
  • Below peers: long-term debt as % of assets. Long-term debt as % of assets of 52.5% ranks 32 of 35 life sciences tools & services companies we cover (median 26.3%).

Latest results: FY2026 Q2

Filed August 5, 2026
Earnings per share
-$0.71 against an average estimate of -$0.90: beat by 21.4%
Revenue
$27m, up 34.2% on a year earlier
Share reaction
-2.9% in the first session after the results on August 5, 2026, against -0.4% for the S&P 500
Guidance given
total Revenue $108m to $114m (FY 2026); gross Margin 80% (FY 2026)
Next report
November 5, 2026

Biodesix's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-3.2%
  • 1 week-3.9%
  • 1 month-23.9%
  • This year+220.3%
  • 1 year+232.7%
  • 5 years-85.6%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$103M
Operating margin
-20.0%
Net margin
-27.0%
EPS (TTM, diluted)
$-3.13

Growth

Revenue growth
+34.5%
Change in growth rate
+5.4 pts

Cash

Free cash flow (TTM)
-$20.2M
FCF margin
-19.7%
Stock pay % of revenue
3.9%

Earnings

Last results
August 5, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Guidance

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Biodesix Inc valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: valued with our growth model, which doesn't carry a Buy/Hold/Sell rating yet.

Valuation models

We value Biodesix Inc as an operating company, with every model that fits that kind of business. Cost of equity 8.9%: the 10-year Treasury yield (4.9%) plus a beta of 0.88 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Growth cash-flow model Revenue for this year and next from analysts' consensus, then growth fading to 2.5%; the operating margin moving to profitable peers'; investment needed per dollar of growth from peers; reduced by a failure probability. For young or fast-growing companies. The starting margin is normalized to between -100% and 60%; net margin is a proxy when operating income is not tagged. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$7.3 ~$3.2–$11 Primary model, counts double
Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. — Does not apply: no positive earnings in the latest twelve months
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: the model gives no positive value
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. — Does not apply: return on equity is not positive
Forward price-to-sales vs peers Next year's consensus sales per share times peers' typical forward price-to-sales; only when earnings are negative. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$39 ~$31–$90 Included, half weight
Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. ~$22 ~$16–$28 Included
Combined value Weighted average of the models that apply: the primary model (growth cash-flow model) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$16 ~$7.3–$39 3 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Biodesix Inc with Life Sciences Tools & Services in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

Valuation multiples over time Market data may be delayed

At fiscal year end 202020212022202320242025Now
Share price$403.20$105.80$46.00$36.80$30.60$6.80$21.78
Market value$18.0bn$290m$194m$151m$198m$51m$193m
+ Net debt (− = net cash)−$22m−$23m−$13m$14m$14m$31m$20m
Enterprise value$17.9bn$267m$181m$165m$212m$82m$213m
Multiples
Price / sales n/m5.3x5.1x3.1x2.8x0.6x1.9x
Price / earnings ———————
Price / free cash flow ———————
EV / EBITDA ———————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

12 /100

Weak moat

How hard Biodesix's competitive advantage looks for rivals to wear away, judged from 7 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Net income has been a median -55.7% of total assets over 6 years.

  • Durability 10 / 20

    Operating margin has been a median -54.7%; its worst year was -162.7%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 6 years, at a median -70.4% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (17 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 5, 2026, after the close. Analysts expect revenue of $27m for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$2.67 +43% $112m +26%
Next −$1.67 +38% $135m +20%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −9.7% on 90 days ago. In the last 30 days, 7 analysts raised Biodesix Inc's forecast and 0 cut it.

Consensus EPS forecast Biodesix Inc, last 90 days
−$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.96 Current fiscal year, 60 days ago: −$2.67 Current fiscal year, 30 days ago: −$2.67 Current fiscal year, 7 days ago: −$2.67 Current fiscal year, Now: −$2.67 −$2.67 Next fiscal year, 90 days ago: −$1.77 Next fiscal year, 60 days ago: −$1.67 Next fiscal year, 30 days ago: −$1.67 Next fiscal year, 7 days ago: −$1.67 Next fiscal year, Now: −$1.67 −$1.67

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$2.96−$1.77
60 days ago −$2.67−$1.67
30 days ago −$2.67−$1.67
7 days ago −$2.67−$1.67
Now −$2.67−$1.67

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.90 −$0.71 +21.4%
Mar 2026 −$1.10 −$0.81 +26.1%
Dec 2025 −$0.87 −$0.49 +43.4%
Sept 2025 −$1.51 −$1.16 +23.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, August 5, 2026
  • Total Revenue FY 2026 $108m to $114m Maintained
    “Total Revenue $108-114M (mid-point is 25% growth)” source
  • Gross Margin FY 2026 about 80% Maintained
    “Gross Margin Maintain ~80%” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

Analyst recommendations

7 analysts, Oct 2026
Buy7100%
Hold00%
Sell00%

Monthly trend

  1. Oct 202677
  2. Sep 202677
  3. Aug 202677
  4. Jul 202677

Counts of recommendations published by analysts covering Biodesix Inc, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
3.4%
of tradable shares
Days to cover
2.09
at average volume
Short interest, 1 month
−2%
to October 15, 2026
Held by institutions
41%
of shares
Held by insiders
40.1%
of shares
Employees
334
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +218.9%

$6.83 on October 31, 2025 to $21.78

ThenNowEffect
Revenue (last 12 months) $77m $103m +34.5%
P/S multiple 0.6x 1.9x +197.6%
Share count 7m 9m −20.3%

Biggest factor: p/s multiple. Loss-making at one end, so the split uses price/sales.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
BDSX−74%−57%−20%−17%−78%+220%
Industry peers (median)+5%−51%−3%−13%−2%+15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
BDSX17%33%42%50%25%55%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
BDSX−87%−83%−58%−44%−86%−49%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since October 28, 2020: 99% from January 20, 2021 to May 14, 2025. Getting back needed a 14086% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$5.46 – $30.60
From 52-week high
−28.8%
vs 50-day average
−17.4%
vs 200-day average
+16.2%
Volatility (1 year)
108%
Beta vs S&P 500
0.99

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±13.0%
After a week
7 up, 5 down
typical move ±14.0%
After a month
6 up, 6 down
typical move ±19.3%
Results releasedNext dayS&P 500 next day5 days21 days
August 5, 2026 −2.9% −0.4% +6.4% +16.3%
May 4, 2026 +34.8% +0.4% +45.4% +45.3%
February 26, 2026 +18.6% −1.0% +22.7% +9.9%
November 3, 2025 +11.3% −1.0% +10.4% +19.2%
August 7, 2025 +2.8% +0.7% +1.8% +10.8%
May 13, 2025 −38.7% +0.8% −24.5% −16.4%
March 3, 2025 −9.2% −2.9% +1.6% −23.6%
January 10, 2025 −16.2% −1.4% −22.3% −35.8%
November 1, 2024 −18.2% +0.2% −19.4% −20.0%
August 7, 2024 +3.1% +1.6% +8.2% +16.4%
May 8, 2024 0.0% +0.6% −1.6% −14.2%
March 1, 2024 +0.6% +0.8% −3.9% −3.2%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Biodesix Inc in five measures

Fundamentals grade C+
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Biodesix Inc
$40M $60M $80M $100M $120M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $44M Revenue (TTM), FY23 Q4: $49.1M Revenue (TTM), FY24 Q1: $54.8M Revenue (TTM), FY24 Q2: $60.9M Revenue (TTM), FY24 Q3: $65.6M Revenue (TTM), FY24 Q4: $71.3M Revenue (TTM), FY25 Q1: $74.5M Revenue (TTM), FY25 Q2: $76.6M Revenue (TTM), FY25 Q3: $80.2M Revenue (TTM), FY25 Q4: $88.5M Revenue (TTM), FY26 Q1: $96.1M Revenue (TTM), FY26 Q2: $102.9M $102.9M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $44M
FY23 Q4 $49.1M
FY24 Q1 $54.8M
FY24 Q2 $60.9M
FY24 Q3 $65.6M
FY24 Q4 $71.3M
FY25 Q1 $74.5M
FY25 Q2 $76.6M
FY25 Q3 $80.2M
FY25 Q4 $88.5M
FY26 Q1 $96.1M
FY26 Q2 $102.9M
Revenue growth, TTM YoY Biodesix Inc
20% 30% 40% 50% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 22.9% Revenue growth, TTM YoY, FY23 Q4: 28.5% Revenue growth, TTM YoY, FY24 Q1: 34.7% Revenue growth, TTM YoY, FY24 Q2: 46.3% Revenue growth, TTM YoY, FY24 Q3: 48.9% Revenue growth, TTM YoY, FY24 Q4: 45.3% Revenue growth, TTM YoY, FY25 Q1: 35.8% Revenue growth, TTM YoY, FY25 Q2: 25.7% Revenue growth, TTM YoY, FY25 Q3: 22.3% Revenue growth, TTM YoY, FY25 Q4: 24.1% Revenue growth, TTM YoY, FY26 Q1: 29.1% Revenue growth, TTM YoY, FY26 Q2: 34.5% 34.5%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 22.9%
FY23 Q4 28.5%
FY24 Q1 34.7%
FY24 Q2 46.3%
FY24 Q3 48.9%
FY24 Q4 45.3%
FY25 Q1 35.8%
FY25 Q2 25.7%
FY25 Q3 22.3%
FY25 Q4 24.1%
FY26 Q1 29.1%
FY26 Q2 34.5%
Operating margin (TTM) Biodesix Inc
-150% -100% -50% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -109.8% Operating margin (TTM), FY23 Q4: -84.2% Operating margin (TTM), FY24 Q1: -65.6% Operating margin (TTM), FY24 Q2: -54.7% Operating margin (TTM), FY24 Q3: -53.0% Operating margin (TTM), FY24 Q4: -48.4% Operating margin (TTM), FY25 Q1: -43.8% Operating margin (TTM), FY25 Q2: -44.5% Operating margin (TTM), FY25 Q3: -40.6% Operating margin (TTM), FY25 Q4: -31.5% Operating margin (TTM), FY26 Q1: -26.0% Operating margin (TTM), FY26 Q2: -20.0% -20.0%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -109.8%
FY23 Q4 -84.2%
FY24 Q1 -65.6%
FY24 Q2 -54.7%
FY24 Q3 -53.0%
FY24 Q4 -48.4%
FY25 Q1 -43.8%
FY25 Q2 -44.5%
FY25 Q3 -40.6%
FY25 Q4 -31.5%
FY26 Q1 -26.0%
FY26 Q2 -20.0%
FCF margin (TTM) Biodesix Inc
-150% -100% -50% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -100.8% FCF margin (TTM), FY23 Q4: -93.3% FCF margin (TTM), FY24 Q1: -83.8% FCF margin (TTM), FY24 Q2: -100.1% FCF margin (TTM), FY24 Q3: -94.9% FCF margin (TTM), FY24 Q4: -72.7% FCF margin (TTM), FY25 Q1: -60.4% FCF margin (TTM), FY25 Q2: -40.7% FCF margin (TTM), FY25 Q3: -36.4% FCF margin (TTM), FY25 Q4: -26.6% FCF margin (TTM), FY26 Q1: -26.1% FCF margin (TTM), FY26 Q2: -19.7% -19.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -100.8%
FY23 Q4 -93.3%
FY24 Q1 -83.8%
FY24 Q2 -100.1%
FY24 Q3 -94.9%
FY24 Q4 -72.7%
FY25 Q1 -60.4%
FY25 Q2 -40.7%
FY25 Q3 -36.4%
FY25 Q4 -26.6%
FY26 Q1 -26.1%
FY26 Q2 -19.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 25 46 55 38 49 71 88 103
EBITDA −24 −20 −38 −47 −38 −29 −22 −15
Operating income −27 −23 −41 −51 −41 −34 −28 −21
Net income −31 −65 −43 −65 −52 −43 −35 −28
Diluted EPS −$13789.96 −$703.78 −$15.80 −$15.50 −$0.64 −$6.64 −$4.67 −$3.13
Growth (year on year)
Revenue — +85.6% +19.6% −29.9% +28.5% +45.3% +24.1% +34.5%
Margins
EBITDA margin −97.5% −44.0% −69.3% −123.0% −77.4% −40.3% −25.1% −14.6%
Operating margin −108.9% −50.3% −75.1% −132.4% −84.2% −48.4% −31.5% −20.0%
Net margin −125.1% −143.7% −79.2% −171.3% −106.2% −60.2% −39.8% −27.0%
Free-cash-flow margin −93.8% −51.2% −55.9% −126.3% −93.3% −72.7% −26.6% −19.7%
Cash flow
Cash from operations −22 −21 −28 −45 −23 −49 −23 −20
Capital spending 1 2 2 3 23 3 0 0
Free cash flow −23 −23 −30 −48 −46 −52 −24 −20
Stock-based pay 0 4 5 6 5 7 4 4
Free cash flow after stock pay −23 −27 −35 −54 −51 −59 −28 −24
Balance sheet
Cash 5 62 33 43 26 26 19 30
Total debt 49 40 10 30 40 40 50 50
Net debt (negative = net cash) 44 −22 −23 −13 14 14 31 20
Diluted shares — 45m 3m 4m 4m 6m 8m 9m

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

1 of 7 checks passed · June 30, 2026
What it owns · $95m
Short-term assets $44mLonger-term assets $52m
What it owes, and who funded it · $95m
Short-term liabilities $15mLonger-term liabilities $71mShareholders' equity $9m
  • Short-term assets cover short-term liabilities $44m of assets due within a year against $15m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $44m short-term assets against $71m of longer-dated liabilities.
  • More cash than debt $30m of cash against $50m of debt.
  • Debt below 40% of shareholders' equity Debt is 547% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 51% to 547% over five years.
  • A year's operating cash flow covers at least 20% of debt −$20m of operating cash flow against $50m of debt.
  • Operating profit covers interest at least five times over Operating income of −$21m against $8m of interest.

From Biodesix Inc's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

R&D spending
11.9%
of revenue
Sales & admin spending
90.6%
of revenue
Days sales outstanding
32 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in life sciences tools & services
Last 12 months unless stated BDSX MDXH HBIO CDXS BNR XGN Median
Revenue, last 12 months $103m $108m $88m $78m $75m $71m $229m
Revenue growth, last 12 months 34.5% 19.8% −1.1% 35.9% 4.7% 20.8% 6.9%
Revenue growth, 3-year average 35.2% — −8.4% −7.8% — 10.3% 2.9%
Revenue growth, latest quarter 34.2% — 11.1% −2.7% — 15.9% 8.5%
Gross margin — 64.5% 58.2% 87.0% 74.7% 58.6% 51.9%
Operating margin −20.0% −13.4% −0.3% −35.6% −10.2% −18.6% −14.3%
Operating margin, 3-year average −39.7% — −21.4% −81.6% — −23.4% −22.4%
Net margin −27.0% −31.1% −11.9% −39.6% −10.3% −26.6% −16.1%
Cash from operations / revenue −19.3% −2.0% 0.7% −13.4% −5.3% −9.1% 1.3%
Free-cash-flow margin −19.7% −3.1% −1.3% −15.7% −6.2% −10.7% −2.2%
Free-cash-flow margin, 3-year average −53.5% — 3.6% −71.6% — −16.3% 0.6%
Stock pay / revenue 3.9% 2.0% 1.6% 9.9% 2.6% 4.1% 4.4%
Change in share count — 52.0% 2.5% 12.9% −100.0% 23.9% 1.0%

Median of all 54 companies we cover in life sciences tools & services. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

54 life sciences tools & services companies
Measure Company Peer median Rank
Revenue growth Growth 34.5% 6.9% 4 of 54
Change in growth rate Growth +5.4pp +0.4pp 8 of 54
Operating margin Profitability -20.0% -14.3% 28 of 52
Net margin Profitability -27.0% -12.2% 33 of 54
Free-cash-flow margin Cash generation -19.7% -1.3% 38 of 54
Stock pay as % of revenue Cash generation 3.9% 4.4% 24 of 53
Long-term debt as % of assets Balance sheet 52.5% 26.3% 32 of 35
Days sales outstanding Balance sheet 32 days 62 days 7 of 48

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Diagnostic Tests $79.2M 89.5% ▲ 22.4%
Development Services $9.3M 10.5% ▲ 40.6%

From Biodesix Inc's 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$90.2M
Institutions reporting
43
Shares held vs prior quarter
▲ 9.8%
Positions opened / closed
10 / 5

Top buyers and sellers, Q2 2026: 24 institutions bought and 18 sold ; the biggest buyer was Soleus Capital Management, L.P (+169K shares) and the biggest seller Aigh Capital Management LLC (−80K). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Aigh Capital Management LLC $15.3M 678K 17.0% ▼ 10.5%
Soleus Capital Management, L.P. $13.2M 586K 14.6% ▲ 40.7%
Telemark Asset Management, LLC $11M 490K 12.2% 0.0%
Aberdeen Group PLC $8.8M 389K 9.7% ▼ 15.2%
Vanguard Capital Management LLC $6.4M 284K 7.1% ▲ 11.4%
Essex Investment Management Co LLC $5.5M 242K 6.0% ▲ 83.1%
Opaleye Management Inc. $4.1M 180K 4.5% ▼ 24.4%
Marshall Wace, LLP $2.6M 116K 2.9% ▼ 18.0%
Perceptive Advisors LLC $2.5M 109K 2.7% New
Jane Street Group, LLC $2.1M 92K 2.3% ▲ 238.5%
Two Sigma Investments, LP $2M 87K 2.2% ▲ 92.0%
Walleye Capital LLC $1.7M 74K 1.9% ▲ 586.8%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Biodesix Inc's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $3.1M 6 trades by 1 insider, last 12 months Insider sales History → $118,381 20 trades by 5 insiders · 0% under pre-set plans
Net ▲ $3M net buying
Insider Date Trade Shares Price Value
Schuler Jack W 10% owner August 12, 2026 Buy 15,000 $24.47 $367,050
Schuler Jack W 10% owner August 11, 2026 Buy 13,700 $24.01 $328,937
Schuler Jack W 10% owner August 10, 2026 Buy 13,900 $24.25 $337,075
Cowie Robin Harper CFO, Sec'y & Treasurer February 23, 2026 Sell 535 $12.78 $6,837
O'Kane Kieran Chief Commercial Officer February 23, 2026 Sell 535 $12.78 $6,837
Pestano Gary Anthony Chief Development Officer February 23, 2026 Sell 556 $12.78 $7,106
Vazquez Chris Chief Accounting Officer February 23, 2026 Sell 211 $12.78 $2,697
Hutton Scott President & CEO February 23, 2026 Sell 1,490 $12.78 $19,042
Cowie Robin Harper CFO, Sec'y & Treasurer February 10, 2026 Sell 941 $10.08 $9,485
Pestano Gary Anthony Chief Development Officer February 10, 2026 Sell 540 $10.08 $5,443
O'Kane Kieran Chief Commercial Officer February 10, 2026 Sell 584 $10.08 $5,887
Hutton Scott President & CEO February 10, 2026 Sell 3,559 $10.08 $35,875

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 2, 2026 estimated from the company's past filing pattern, not announced

  • August 5, 2026
  • May 4, 2026
  • February 26, 2026
  • November 3, 2025
  • August 7, 2025
  • May 13, 2025

Recent SEC filings

Data status

When each part of this page on Biodesix Inc was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Biodesix Inc in brief

What does Biodesix Inc do?
Biodesix Inc is a US-listed company in the life sciences tools & services industry. Its financial year ends in December.
What is Biodesix Inc's stock ticker?
Biodesix Inc trades under the ticker BDSX on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Biodesix Inc's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Biodesix Inc reported revenue of $103M, 34.5% higher than a year earlier, according to its SEC filings.
What is Biodesix Inc's free cash flow?
Biodesix Inc's free-cash-flow margin is -19.7% of revenue over the trailing twelve months, ranking 38 of the 54 life sciences tools & services companies we cover.
Who are Biodesix Inc's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Aigh Capital Management LLC, Soleus Capital Management, L.P. and Telemark Asset Management, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Biodesix Inc's market cap?
On November 2, 2026, Biodesix Inc's market capitalisation was about $193M and net debt of $20M. Market figures come from third-party market data and may be delayed.
How much debt does Biodesix Inc have?
Biodesix Inc's debt-to-equity ratio is 546.8%, from its latest balance sheet (51.1% five years earlier). The financial health section below sets out its other solvency checks.
Who are Biodesix Inc's competitors?
In our Life Sciences Tools & Services peer group, the companies closest to Biodesix Inc are Mdxhealth SA, Harvard Bioscience Inc, Codexis, Inc., Burning Rock Biotech Ltd and Exagen Inc. The side-by-side comparison below sets their revenue, margins and growth against Biodesix Inc's.
Are insiders buying or selling Biodesix Inc stock?
Over the last 12 months, Biodesix Inc's directors and officers reported 6 open-market purchases and 20 sales on Form 4. The insider trading page charts every trade.
When is Biodesix Inc's next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Biodesix Inc announces its own schedule.